Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Cost of atopic dermatitis and eczema in the United States.
The annual cost of medical services and prescription drugs for the treatment of AD/E to private insurance and Medicaid payers in the United States is identified and is similar to those of other diseases such as emphysema, psoriasis, and epilepsy.
- W. Abramovits
- Medicine, BiologyJournal of the American Academy of Dermatology
The current understanding of its pathophysiology has provided clinicians with the ability to construct more rational therapeutic interventions, including multiple-agent regimens that provide both immediate relief and effective long-term management.
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study.
Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle.
Coexistence of lichen planus and systemic lupus erythematosus.
A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults.
MAS063DP cream was confirmed to be a safe and effective treatment for mild to moderate atopic dermatitis in adults and statistically more effective than vehicle in all outcomes at all time points.
Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients.
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial†
Patients with psoriasis value rapid and complete skin clearance. No head‐to‐head studies have focused on early responses to interleukin (IL)‐17 vs. IL‐23 inhibitors.
Efficacy of tofacitinib in treatment of alopecia universalis in two patients
- A. Gupta, J. Carviel, W. Abramovits
- Medicine, BiologyJournal of the European Academy of Dermatology…
- 1 August 2016
The targeted kinase inhibitor tofacitinib, in current use for treatment of other immune diseases, has been hypothesized as a viable option for AA, AT and AU therapy and a few case reports support this.